DelveInsight’s report, “Acute Pain Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the Acute Pain landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
Additionally, it examines Acute Pain market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.
To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Pain Market Forecast
Some of the key facts of the Acute Pain Market Report:
The Acute Pain market is anticipated to increase from approximately USD 4.5 billion in 2025 to around USD 15.5 billion by 2036, registering a compound annual growth rate (CAGR) of 12% during the forecast period from 2026 to 2036.
In February 2026, Cidara Therapeutics announced MK-1406 (CD388) is currently being evaluated in the Phase III ANCHOR study (NCT07159763).
In January 2026, Merck announced The company has successfully completed a cash tender offer, conducted via its subsidiary, for the acquisition of all outstanding common shares of Cidara Therapeutics.
In March 2026, Cocrystalpharma announced The company plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal Acute pain with an additional Phase IIa study.
In February 2026, The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for mCombriax, a vaccine developed by Moderna, for the prevention of influenza disease.
In April 2025, Roche announced that New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza showing a reduction in the transmission of influenza viruses.
The total number of incident cases of acute pain in the 7MM were around 181,208,000 in 2025.
The total incident cases of acute pain in the US were around 87,410,000 in 2025. These cases are anticipated to increase in the upcoming years.
In 2025, approximately 13% of the incident cases of acute pain were reported in Germany.
In 2025, type-specific incident cases of acute pain in the 7MM comprised 89,907,500; 44,622,400; and 139,849,200 cases for postoperative pain, trauma pain, and acute medical illness, respectively.
In 2025, there were ~20%; ~15% and ~10% cases for mild, moderate and severe, respectively, in Japan out of 7MM.
In Germany in 2025, approximately 20% of acute pain cases were classified as mild, 15% as moderate, and around 10% as severe out of 7MM.
Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others.
Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others
The Acute Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.
In 2023, type-specific incident cases of Acute Pain in the United States were distributed as approximately 60% for trauma-related pain and 40% for other causes.
In the United States, severity-specific incident cases of Acute Pain were highest for moderate pain, totaling approximately 25 million cases in 2023.
In the seven major markets, moderate to severe cases accounted for approximately 60% of the total diagnosed cases in 2023.
Acute Pain Overview
Acute Pain is the immediate pain experienced by patients following a surgical procedure, typically lasting from a few hours to several days. It results from tissue injury, inflammation, and nerve stimulation caused during surgery. The intensity and duration of pain can vary depending on the type of surgery, patient health, and individual pain tolerance.
Get a Free sample for the Acute Pain Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/acute-pain-market
Acute Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acute Pain Epidemiology Segmentation:
The Acute Pain market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Incident Cases of Acute Pain
Total Incident Cases of Acute Pain by Type
Severity Specific Incident Cases of Acute Pain
Total Treated CasesIn of Acute Pain
Download the report to understand which factors are driving Acute Pain epidemiology trends @ Acute Pain Epidemiology Forecast
Acute Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acute Pain Therapies and Key Companies
JOURNAVX (suzetrigine): Vertex Pharmaceuticals
ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
NTM-001: Neumentum
CPL-01: Cali Biosciences
PRF-110: PainReform
Discover more about therapies set to grab major Acute Pain market share @ Acute Pain Treatment Landscape
Acute Pain Market Drivers
Rising Number of Surgical Procedures: Increasing volumes of orthopedic, cardiovascular, cosmetic, and general surgeries are driving demand for effective acute pain management therapies.
Growing Incidence of Trauma and Injury Cases: Higher rates of road accidents, sports injuries, fractures, and emergency room visits are contributing to the need for rapid pain relief solutions.
Advancements in Non-Opioid Pain Management: Development of novel non-opioid analgesics and multimodal pain management approaches is expanding treatment options and improving patient outcomes.
Increasing Focus on Enhanced Recovery After Surgery (ERAS) Programs: Hospitals are adopting ERAS protocols that emphasize effective postoperative pain control and reduced hospital stays.
Acute Pain Market Barriers
Concerns Regarding Opioid Abuse and Dependence: Strict regulations and concerns over addiction risks associated with opioid analgesics may limit their utilization.
Stringent Regulatory Requirements: Regulatory agencies require extensive safety and efficacy data, increasing development timelines and costs for new pain therapies.
Side Effects Associated with Pain Medications: Adverse effects such as nausea, gastrointestinal complications, respiratory depression, and sedation can impact treatment adoption.
Availability of Generic Alternatives: The widespread presence of low-cost generic pain medications creates pricing pressure for branded products.
Scope of the Acute Pain Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others
Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others
Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies
Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Acute Pain Unmet Needs, KOL’s views, Analyst’s views, Acute Pain Market Access and Reimbursement
To know more about Acute Pain companies working in the treatment market, visit @ Acute Pain Clinical Trials and Therapeutic Assessment
Table of Contents
1. Acute Pain Market Report Introduction
2. Executive Summary for Acute Pain
3. SWOT analysis of Acute Pain
4. Acute Pain Patient Share (%) Overview at a Glance
5. Acute Pain Market Overview at a Glance
6. Acute Pain Disease Background and Overview
7. Acute Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Pain
9. Acute Pain Current Treatment and Medical Practices
10. Acute Pain Unmet Needs
11. Acute Pain Emerging Therapies
12. Acute Pain Market Outlook
13. Country-Wise Acute Pain Market Analysis (2022–2036)
14. Acute Pain Market Access and Reimbursement of Therapies
15. Acute Pain Market Drivers
16. Acute Pain Market Barriers
17. Acute Pain Appendix
18. Acute Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/
